MedTrace Logo

Phase 1 Imaging Study of 89Zr-DFO-HuMab-5B1 With HuMab-5B1

NCT02687230 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2021-08-31

No results posted yet for this study

Summary

Open label, nonrandomized, dose-escalation trial of MVT-2163 and MVT-5873 used in performing PET scans. The study is designed to determine the best time and dose of these agents that result in the best PET image of a tumor. Subjects will be seen on days 1, 2, 4, and 7 for imaging and a clinical assessment. The last study visit is on day 28.

Conditions

  • Pancreatic Carcinoma
  • Tumors That Express CA19-9

Interventions

DRUG

MVT-2163

MVT-2163 is administered intravenously as a PET imaging agent

DRUG

MVT-5873

MVT-5873 is administered intravenously as a non-radioactive blocking agent prior to administration of MVT-2163

Sponsors & Collaborators

  • SciQuus Oncology

    collaborator UNKNOWN

  • BioNTech Research & Development, Inc.

    lead INDUSTRY

Principal Investigators

  • BioNTech Responsible Person · BioNTech SE

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-11
Primary Completion
2017-05-05
Completion
2017-05-05

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02687230 on ClinicalTrials.gov